S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

NanoViricides Stock Forecast, Price & News

+0.06 (+2.29%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
53,136 shs
Average Volume
88,036 shs
Market Capitalization
$30.89 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter.

NanoViricides logo

About NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.


See More Headlines

Industry, Sector and Symbol

Stock Exchange
Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.60 per share


Net Income
$-8.82 million
Pretax Margin




Free Float
Market Cap
$30.89 million

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSEAMERICAN:NNVC) released its earnings results on Monday, November, 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.03.
View NanoViricides' earnings history

When did NanoViricides' stock split? How did NanoViricides' stock split work?

NanoViricides's stock reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Who are NanoViricides' key executives?

NanoViricides' management team includes the following people:
  • Anil R. Diwan, Executive Chairman, President, CEO & Secretary
  • Meeta R. Vyas, Chief Financial & Accounting Officer
  • Randall W. Barton, Chief Scientific & Regulatory Officer
  • Jayant Tatake, Vice President-Research & Development

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), iBio (IBIO) and Moderna (MRNA).

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

Who are NanoViricides' major shareholders?

NanoViricides' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%).
View institutional ownership trends for NanoViricides

Which major investors are selling NanoViricides stock?

NNVC stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for NanoViricides
or view top insider-selling stocks.

How do I buy shares of NanoViricides?

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $2.68.

How much money does NanoViricides make?

NanoViricides has a market capitalization of $30.89 million. The company earns $-8.82 million in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does NanoViricides have?

NanoViricides employs 12 workers across the globe.

What is NanoViricides' official website?

The official website for NanoViricides is www.nanoviricides.com.

Where are NanoViricides' headquarters?

NanoViricides is headquartered at 1 Controls Dr, SHELTON, CT 06484-6153, United States.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at (203) 937-6137, via email at [email protected], or via fax at 203-859-5095.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.